PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday, October 10, 2017 in New York City.

Members of Agile’s executive team will review clinical data and discuss the commercialization plan for Twirla^®, the company's lead investigational once weekly low-dose prescription contraceptive patch.  Management will be joined by leading external experts who will provide clinical perspectives on Twirla, as well as regulatory and market access insights into today’s contraceptive marketplace.

To access the live webcast, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. A replay will be available on the company’s website.

Event Details
Date:	Tuesday, October 10, 2017
Time:	11:00 a.m. – 1:30 p.m. ET
Location:	New York City

Speakers will include:
Alfred Altomari	Chairman and CEO, Agile Therapeutics
Elizabeth Garner, M.D., MPH	Senior Vice President, Chief Medical Officer, Agile Therapeutics
Renee Selman	Chief Commercial Officer, Agile Therapeutics
Robin Kroll, M.D., FACOG	Director, Seattle Women’s: Health, Research, Gynecology;
	SECURE Trial Investigator
David J. Portman, M.D., FACOG	Director Emeritus, Columbus Center for Women’s Health
	Research; CEO and Chief Medical Officer, Sermonix
	Pharmaceuticals
Minnie Baylor-Henry, J.D., R.Ph	Executive Partner, YourEncore; Former Director, Division of
	Drug Marketing, Advertising and Communications (DDMAC),
	Food and Drug Administration; Former Worldwide Vice
	President, Regulatory Affairs, Johnson & Johnson
Adaeze Enekwechi, PhD, MPP	VP, McDermottPlus Consulting in Washington,D.C.; Former
	Associate Director for Health Programs, White House Office of
	Management and Budget under President Obama

Analysts and institutional investors seeking more information about this event should contact Matt Ventimigila by phone or email: MVentimiglia@lazarpartners.com, or 212-599-1265.

About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com.  The company may occasionally disseminate material, nonpublic information on the company website.

Follow Agile on Twitter: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.

About Twirla^®
Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational once-weekly prescription contraceptive patch. AG200-15 is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE), a synthetic estrogen, and levonorgestrel (LNG), a type of progestin, a synthetic steroid hormone. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.

Contact:
Mary Coleman 
Agile Therapeutics, Inc.
609-356-1921

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.